Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment
Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment
复制标题
DOI：
10.3233/jad-180325
复制
发表时间：
2019-01-01
影响因子：
4
通讯作者：
Otto, Markus
中科院分区：
文献类型：
--
作者：
Oeckl, Patrick;Halbgebauer, Steffen;Otto, Markus
阿尔茨海默病（AD）的可靠血液生物标志物缺失。我们测量了AD（n = 28）、额颞叶痴呆（bvFTD，n = 35）、帕金森病（n = 11）、路易体痴呆（n = 19）和对照组（n = 34）患者的星形胶质细胞GFAP。血清GFAP在AD（p < 0.001）和DLB/PDD（p < 0.01）中升高，脑脊液GFAP在所有神经退行性疾病中升高（p < 0.001）。血清GFAP水平与简易精神状态检查量表评分相关（r =-0.42，p < 0.001），可作为临床随访指标。血清GFAP对AD与bvFTD的敏感性和特异性分别为89%和79%，可能是AD和bvFTD鉴别诊断的第一个血液生物标志物。
Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r = -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.